Loading clinical trials...
Loading clinical trials...
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Conditions
Interventions
Temozolomide
hypofractionated radiation therapy
+2 more
Locations
5
United States
Northwestern University
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Northwestern Lake Forest Hospital
Lake Forest, Illinois, United States
Edward Cancer Center
Naperville, Illinois, United States
Central Dupage Hospital
Warrenville, Illinois, United States
Start Date
December 14, 2011
Primary Completion Date
September 12, 2018
Completion Date
September 12, 2018
Last Updated
March 12, 2020
NCT02015819
NCT01234805
NCT00045110
NCT00823797
NCT02194452
NCT02175745
Lead Sponsor
Northwestern University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions